Sun Pharma Showcases Resilience Amid Profit Decline with LEQSELVI Launch

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions rose 6%. Total income increased to Rs 14,316 crore. Growth was driven by strong Indian market performance and US launch of LEQSELVI for alopecia areata, boosting dermatology portfolio.

Devdiscourse News Desk | New Delhi | Updated: 31-07-2025 16:27 IST | Created: 31-07-2025 16:27 IST

Sun Pharma Showcases Resilience Amid Profit Decline with LEQSELVI Launch — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Country:
India

Sun Pharmaceutical Industries on Thursday announced a consolidated net profit drop of 20% to Rs 2,279 crore for the first quarter ending June 30, 2025. This compares to a net profit of Rs 2,836 crore in the same quarter last year.

Despite the profit decline, Sun Pharma's adjusted net profit, excluding exceptional items, rose to Rs 2,996 crore, marking a 6% year-on-year increase. Total income for the quarter reached Rs 14,316 crore, up from Rs 13,185 crore in the year-ago period, the company confirmed in a regulatory filing.

Chairman and Managing Director Dilip Shanghvi highlighted strong market performance, particularly in India, and the successful US launch of LEQSELVI, a treatment for severe alopecia areata, which is set to enhance their dermatology portfolio. During the quarter, significant sales were recorded in both the Indian and US markets, contributing to the company's robust growth story.

(With inputs from agencies.)